B-cell-targeted therapy in rheumatic diseases

Authors: Risselada, Anna P; Kallenberg, Cees GM

Source: Future Rheumatology, Volume 1, Number 5, October 2006 , pp. 635-642(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

During the last decade, the role of B cells in the pathogenesis of autoimmune diseases has been highlighted. Treatment selectively targeting B cells has been made available through the development of (humanized) monoclonal antibodies. Rituximab (anti-CD20) depletes mature B cells and has been successfully used in several systemic autoimmune diseases. At present, only one randomized controlled trial has been performed, and more trials are planned. Additionally, other B-cell targeting monoclonals, such as epratuzumab (anti-CD22) and belimumab (anti-BLyS/BAFF) are being tested. In this article, the presently published (open) studies using these monoclonal therapies are reviewed and future perspectives in this area are discussed.

Keywords: B-cell depletion; belimumab; epratuzumab; rituximab; systemic autoimmune diseases; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.2217/17460816.1.5.635

Publication date: 2006-10-01

More about this publication?

Future Rheumatology provides analysis and commentary on our understanding of disease mechanisms, emerging therapeutic strategies and new diagnostic approaches. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this expanding area of specialization.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites